Gene therapy for wet AMD: Long-Term safety check underway
NCT ID NCT04645212
First seen Feb 12, 2026 · Last updated May 08, 2026 · Updated 11 times
Summary
This study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD) in an earlier trial. Researchers are monitoring long-term safety and how well the treatment controls vision loss and retinal swelling over time. The goal is to see if this one-time gene therapy can reduce the need for frequent eye injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adverum Clinical Site
Bakersfield, California, 93309, United States
-
Adverum Clinical Site
Beverly Hills, California, 90211, United States
-
Adverum Clinical Site
Lakewood, Colorado, 80228, United States
-
Adverum Clinical Site
Deerfield Beach, Florida, 33064, United States
-
Adverum Clinical Site
Reno, Nevada, 89502, United States
-
Adverum Clinical Site
Philadelphia, Pennsylvania, 19107, United States
-
Adverum Clinical Site
Nashville, Tennessee, 37203, United States
-
Adverum Clinical Site
Bellaire, Texas, 77401, United States
-
Adverum Clinical Site
The Woodlands, Texas, 77384, United States
Conditions
Explore the condition pages connected to this study.